Nu Skin Enterprises (NUS) Cash & Equivalents (2009 - 2026)

Nu Skin Enterprises has disclosed Cash & Equivalents across 18 years of filings, most recently posting $198.7 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $198.7 million, down 2.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $198.7 million (down 2.51% YoY), and the FY2025 annual result was $238.6 million, up 27.69% from the prior year.
• Cash & Equivalents came in at $198.7 million for Q1 2026 at Nu Skin Enterprises, down from $238.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $363.9 million in Q2 2022 to a low of $186.9 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $235.6 million (2023), against an average of $246.4 million.
• Across the five-year window, Cash & Equivalents tumbled 35.27% in 2023 and rose 27.69% in 2025, its largest moves.
• Nu Skin Enterprises' Cash & Equivalents stood at $264.7 million in 2022, then decreased by 3.27% to $256.1 million in 2023, then dropped by 27.02% to $186.9 million in 2024, then grew by 27.69% to $238.6 million in 2025, then declined by 16.75% to $198.7 million in 2026.
• The last three Cash & Equivalents figures came in at $198.7 million (Q1 2026), $238.6 million (Q4 2025), and $251.8 million (Q3 2025), per Business Quant data.